A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, an ...